The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,920.00
Bid: 1,919.00
Ask: 1,920.00
Change: 15.00 (0.79%)
Spread: 1.00 (0.052%)
Open: 1,916.00
High: 1,927.00
Low: 1,903.00
Prev. Close: 1,905.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

24 Jan 2022 12:45

RNS Number : 4069Z
Hikma Pharmaceuticals Plc
24 January 2022
 

TR-1: Standard form for notification of major holdings

 

 LONDLONDON, 24 January 2022 - Hikma Pharmaceuticals PLC (LEI:549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) announces as follows:

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Hikma Pharmaceuticals PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Details of person subject to the notification obligation

Name

The Capital Group Companies, Inc.

City and country of registered office (if applicable)

Los Angeles, USA

4. Full name of shareholder(s)  (if different from 3.)

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached:

20/01/2022

6. Date on which issuer notified (DD/MM/YYYY):

21/01/2022

7. Total positions of person(s) subject to the notification obligation:

 

% of voting rights attached to shares

(total of 8.A)

% of voting rights through financial instruments

(total of 8.B.1 + 8.B.2)

Total of both in %

(8.A + 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

4.92%

0.00%

4.92%

231,498,055

Position of previous notification (if applicable)

9.64%

0.00%

9.64%

 

       

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Voting rights attached to shares

Class/type of shares ISIN code (if possible)

Number of voting rights

% of voting rights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00B0LCW083 Common Stock

 

11,385,712

 

4.92%

 

 

 

 

 

SUBTOTAL 8.A

11,385,712

4.92%

 

B 1: Financial Instruments DTR5.3.1R (1) (a)

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

N/A

 

 

 

 

 

 

SUBTOTAL 8.B.1

 

 

 

B 2: Financial Instruments with similar economic effect DTR5.3.1R (1) (b)

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Physical or cash settlement

Number of voting rights

% of voting rights

N/A

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

       

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

 

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Capital Research and Management Company

 

 

 

Total

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional information:

 

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of five investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl, Capital International K.K, and Capital Group Private Client Services, Inc. CGII management companies and CB&T primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based investment management company that is a registered investment adviser and an affiliated federally chartered bank.

Neither CGC nor any of its affiliates own shares of your company for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

 

 

 

Place of completion

Los Angeles

Date of completion

21/01/2022

       

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUSSURUAUAUAR
Date   Source Headline
6th Feb 201712:47 pmRNSHolding(s) in Company
18th Jan 20179:11 amRNSHikma receives approval for Sodium Oxybate
20th Dec 20163:24 pmRNSDirector/PDMR Shareholding
20th Dec 201611:00 amRNSHolding(s) in Company
20th Dec 201610:47 amRNSDirector/PDMR Shareholding
13th Dec 20161:46 pmRNSDirector/PDMR Shareholding
12th Dec 20164:06 pmRNSDirector/PDMR Shareholding
7th Dec 20169:35 amRNSDirector/PDMR Shareholding
6th Dec 20166:04 pmRNSTotal Voting Rights
5th Dec 201612:34 pmRNSDirector/PDMR Shareholding
2nd Dec 20165:42 pmRNSDirector/PDMR Shareholding
28th Nov 20169:59 amRNSDirector/PDMR Shareholding
22nd Nov 20167:00 amRNSHikma announces agreement with Vectura
16th Nov 201611:12 amRNSAdditional Listing
11th Nov 20162:48 pmRNSTotal Voting Rights
10th Nov 20167:00 amRNSTrading Statement
3rd Oct 20164:37 pmRNSBlock listing Interim Review
28th Sep 20165:12 pmRNSDirector/PDMR Shareholding
28th Sep 20169:09 amRNSDirector/PDMR Shareholding
26th Sep 201610:18 amRNSDirector/PDMR Shareholding
22nd Sep 20163:35 pmRNSDirector/PDMR Shareholding
20th Sep 20167:00 amRNSBoard appointment and succession
16th Sep 20165:32 pmRNSDirector/PDMR Shareholding
15th Sep 20164:36 pmRNSDirector/PDMR Shareholding
8th Sep 20165:18 pmRNSDirector/PDMR Shareholding
6th Sep 20165:52 pmRNSDirector/PDMR Shareholding
6th Sep 20164:02 pmRNSTotal Voting Rights
1st Sep 201610:18 amRNSDirector/PDMR Shareholding
26th Aug 20164:28 pmRNSDirector/PDMR Shareholding
26th Aug 20169:47 amRNSDirector/PDMR Shareholding
24th Aug 20167:00 amRNSHalf-year Report
10th Aug 20169:22 amRNSNotice of Results
3rd Aug 20165:18 pmRNSTrading Statement
21st Jul 20167:00 amRNSRegulatory approval of Hikma's colchicine upheld
20th Jul 20167:00 amRNSLaunch of Generic Xeloda® Tablets in the US
27th Jun 20167:01 amRNSDirector/PDMR Shareholding
27th Jun 20167:00 amRNSTotal Voting Rights
20th Jun 20167:00 amRNSDirector/PDMR Shareholding
7th Jun 20164:44 pmRNSTotal Voting Rights
24th May 20167:00 amRNSDirector/PDMR Shareholding
19th May 201612:15 pmRNSFurther re Colchicine Litigation
19th May 201610:17 amRNSDirector/PDMR Shareholding
18th May 20164:25 pmRNSDirector/PDMR Shareholding
12th May 20163:14 pmRNSResult of AGM
12th May 20167:00 amRNSAGM Statement
9th May 20164:05 pmRNSDirector/PDMR Shareholding
6th May 20169:12 amRNSDoc re. Bond Guarantor Group
29th Apr 20165:40 pmRNSDirector/PDMR Shareholding
28th Apr 20162:58 pmRNSDirector/PDMR Shareholding
25th Apr 20164:19 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.